Ashwagandha

Small molecule

SSutter Health

Ashwagandha is one of 51 small molecule programs targeting Periodontitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PeriodontitisActive, not recruiting

Ovarian CancerActive, not recruiting

PeriodontitisPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

8 2

Novantrone

Pfizer

Phase 3

3 3

Piqray

Novartis

Phase 3

1 4

Liposomal Doxorubicin

Eli Lilly

Phase 3

9 5

Cediranib

AstraZeneca

Phase 3

6 6

Carboplatin/paclitaxel

AstraZeneca

Phase 3

1 7

IV Iron

Pfizer

Phase 3

1 8

Salvage Chemotherapy

Daiichi Sankyo

Phase 3

1 9

TLK286

TTelik

Phase 3

5 10

Sofetabart Mipitecan

Eli Lilly

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Ovarian Cancer

NCT05610735

Clinical

Trials by Indication[1]

Periodontitis1 trial

Effect of Ashwagandha on Salivary Antioxidant and Serum c Reactive Protein in Chronic Generalized Periodontitis

Completed·TTatyasaheb Kore Dental College·Phase 1/2·NCT03533972·50 enrolled

Cognitive Dysfunction1 trial

Ashwagandha for Cognitive Dysfunction

Unknown status·SSutter Health·Phase 2·NCT04092647·80 enrolled

Ovarian Cancer1 trial

Combination Therapy for Recurrent Ovarian Cancer

Recruiting·SSham Sunder Kakar·Phase 1/2·NCT05610735·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ashwagandha. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ashwagandha compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ashwagandha. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sutter Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SSutter Health

Ashwagandha

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Periodontitis1 trial

Cognitive Dysfunction1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News